A5004842966- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Antifungal resistance and susceptibility
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Fungal Infections and Studies
- Lung Cancer Diagnosis and Treatment
- Clostridium difficile and Clostridium perfringens research
- Emergency and Acute Care Studies
- Acute Lymphoblastic Leukemia research
- Lung Cancer Research Studies
- Blood transfusion and management
- Blood donation and transfusion practices
- Sepsis Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Antibiotic Use and Resistance
- Biomedical and Engineering Education
- COVID-19 Clinical Research Studies
- Gastric Cancer Management and Outcomes
- Pneumonia and Respiratory Infections
- Nosocomial Infections in ICU
University of Cologne
2019-2025
University Hospital Cologne
2016-2025
FOM University of Applied Sciences for Economics and Management
2019-2025
QUIRIS Healthcare
2020-2025
Heinrich Heine University Düsseldorf
2019-2023
Düsseldorf University Hospital
2019-2023
Centrum für Integrierte Onkologie
2018-2023
BackgroundWe analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).Patients and methodsALK-rearranged stage IIIB/IV NSCLC patients were with next-generation sequencing fluorescence situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) overall (OS) determined total cohort treatment-related sub-cohorts. Cox regression carried out to exclude...
Candida species are responsible for fungal diseases and the development of nosocomial bloodstream infections. Treatment is resource-intensive economically challenging healthcare systems. Cost analyses drugs against candidiasis, such as rezafungin, thus great interest to payers.We conducted a cost-of-illness study patients with infections based on real-word data Department I Internal Medicine, University Hospital Cologne (Germany) between 2016 2021. Health-economic parameters were analysed...
Abstract Background Despite advances in antifungals, Candida infections still have a high mortality rate of up to 40%. The ECMM III study Europe investigated the changing epidemiology and outcomes, highlighting need understand manage these infections. Methods In this observational cohort study, participating hospitals enrolled first ten consecutive adults with confirmed candidemia. Data collected included patient demographics, risk factors, hospital stay length (with 90-day follow-up),...
Invasive fungal infections such as candidemia and invasive candidiasis are associated with prolonged hospital stays due to the consistent need for treatment high mortality rates. Consequently, they pose major challenges healthcare system in general hospitals particular. In contrast actual necessary daily infusion of conventional antimycotics, innovative antimycotics rezafungin offer potential early outpatient treatment. By shifting care sector at an earlier stage, both inpatient resources...
Renal insufficiency is one of the most common complications in treatment multiple myeloma (MM). The administration isatuximab showed improved patient outcome regarding occurrence renal insufficiency. Building on results ICARIA-MM study, aim this study was to quantify potential cost savings due a prevented progress Real-life accounting data University Hospital Cologne (Germany) inpatients with MM between 2016 and 2020 were analyzed presence health-economic impact less severe filtration German...
Abstract Background Over the last century infectious diseases have been kept under control in industrialized countries thanks to advances hygiene, prevention and antimicrobial treatments. However, emergence of HIV, COVID-19 pandemic, rise resistant bacteria exemplify that continue pose a global threat. A comprehensive understanding caseload, spectrum economic impact they is required develop strategies for managing resilient healthcare system. Objectives (i) determine proportion adult...
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. The goal PBSC mobilization is to allow collection sufficient CD34+ cells proceed transplantation. current regimen with granulocyte colony-stimulating factor (G-CSF), alone or combination chemotherapy, still fails 10-25% patients. Plerixafor able rescue most these patients from failure. In this study, we investigated impact plerixafor on cost and...
The introduction of new and innovative treatment options for cancer patients is accompanied by a tremendous increase in healthcare costs. Consequently, financing approaches are strongly needed to reduce the burden on system. biosimilars - biological drugs containing active substance an already approved reference drug can potentially relieve systems. Calculating costs three frequently used biosimilars, we simulated health-economic impact real world German system.Based available analyses,...
Complications after surgery for esophageal cancer are associated with significant resource utilization. The aim of this study was to analyze the economic burden two frequently used endoscopic treatments anastomotic leak management surgery: Treatment a Self-expanding Metal Stent (SEMS) and Endoscopic Vacuum Therapy (EVT).Between January 2012 December 2016, we identified 60 German-Diagnosis Related Group (G-DRG) cases patients who received SEMS / or EVT leaks. Direct costs per case were...
Abstract Purpose First detected in China 2019, the novel coronavirus disease (COVID-19) has rapidly spread globally. Since then, healthcare systems are exposed to major challenges due scarce personnel and financial resources. Therefore, this analysis intended examine treatment costs of COVID-19 inpatients a German single centre during first pandemic wave 2020 from payer perspective. Potential cost savings were assessed considering administration remdesivir according European Medicines Agency...
Mucormycosis is a difficult-to-diagnose life-threatening disease with high morbidity and mortality. Adherence to guidelines that lead through complex management support clinical decisions however rarely reported. By applying the EQUAL Score, our study evaluates of mucormycosis at University Hospital Cologne, Germany.We performed retrospective chart review patients Cologne. Data collection comprised items for quality assessment in according Score economics.Of 29 identified, 27 were documented...
Mobilization and collection of peripheral blood stem cells is part the standard treatment procedure for non-Hodgkin's lymphoma patients eligible high-dose chemotherapy with autologous cell transplantation. usually achieved and/or cytokines, but plerixafor might be added in case poor mobilization. Due to high cost several institutions have developed their own management pathway optimize use plerixafor. Such models are however rarely generalizable; a multi-center, European, non-interventional...
Intravenous bridging strategies increase exposure of antifungal prophylaxis in high-risk hematological patients. The cost-effectiveness such has not been analyzed.A recent study compared the impact oral posaconazole (POS) and with intravenous micafungin (POS-MIC) as prophylactic regimens patients undergoing allogeneic stem cell transplantation (aSCT). Based on data from Cologne Cohort Neutropenic Patients (CoCoNut), a health economic evaluation direct treatment costs was performed to analyze...
9085 Background: The Network Genomic Medicine (NGM) Lung Cancer is a health care provider network offering comprehensive next generation sequencing (NGS)-based multiplex genotyping on central diagnostics platform in Cologne for inoperable lung cancer patients (pts) Germany. Methods: NGS panel used consists of 14 genes and 102 amplicons to cover potentially targetable aberrations. Mutation analyses were run an Illumina (MySeq) platform, FISH performed separately. In 2015, we have started the...
In the past decades, highly innovative treatments in field of diffuse large B-cell lymphoma (DLBCL) became available clinical practice. The aim this study was to assess cost-benefit relation third-line interventions DLBCL from a German payer perspective.Clinical benefit allogeneic stem cell transplantation (alloSCT), chimeric antigen receptor T cells therapy (CAR T) [tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel)] best supportive care (BSC) assessed terms median overall...
9018 Background: KRAS mutations in non-small cell lung cancer (NSCLC) still remain therapeutically untargetable. Assuming that these are not mutually exclusive with other driver aberrations, we set out this study order to describe and analyze co-occurring their potential therapeutic impact. In a subset of patients co-occuring mutations, performed additionally whole-exome sequencing (WES) define clonal evolutional status the mutations. Results were compared data from The Cancer Genome Atlas'...
Summary Background Isavuconazole (ISA) is a frequently used antifungal agent for the treatment of invasive fungal diseases (IFDs). However, hospital reimbursement data ISA limited. Objectives The primary objective this study was to analyse different perspectives relevant stakeholders and (dis)incentives administration in Germany. To that aim, health economic effects using from management perspective were analysed. Patients/Methods Based on principal‐agent theory (PAT), (a) patient...